Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7228MR)

This product GTTS-WQ7228MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7228MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12049MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ957MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ1711MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ1973MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ10592MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5350MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ15747MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ13680MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW